Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J B Porter

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
Bone Marrow Transplantation|March 29, 2000
One antigen mismatched related donor bone marrow transplant in a patient with acute lymphoblastic leukaemia and beta-thalassaemia major: potential cure of both marrow disordersP D Kottaridis, K Peggs, A Lawrence, et al.
The British Journal of Surgery|June 12, 2013
Raised haematocrit concentration and the risk of death and vascular complications after major surgeryK M Musallam, J B Porter, P M Sfeir, et al.
British Journal of Haematology|October 16, 1999
Role of FcgammaRI (CD64) in erythrocyte elimination and its up-regulation in thalassaemiaE Wiener, D Allen, R J Porter, et al.
Journal of Medicinal Chemistry|August 20, 1993
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potentialP S Dobbin, R C Hider, A D Hall, et al.
British Journal of Haematology|May 1, 1985
The kinetics of unmatched and HLA-matched 111in-labelled homologous platelets in recipients with chronic marrow hypoplasia and anti-platelet immunityA M Peters, J B Porter, S H Saverymuttu, et al.
British Journal of Haematology|September 1, 1993
Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyridin-4-one, CP94, relates to differing metabolism of the iron chelating siteJ B Porter, R D Abeysinghe, K P Hoyes, et al.
Annals of Hematology|October 23, 2012
Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudyJ B Porter, M S Elalfy, A T Taher, et al.
Circulation|October 6, 2009
Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia majorP Kirk, M Roughton, J B Porter, et al.
American Journal of Hematology|November 10, 2010
Quality of life in thalassemia: a comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US normsA Sobota, R Yamashita, Y Xu, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Bone Marrow Transplantation|March 29, 2000
One antigen mismatched related donor bone marrow transplant in a patient with acute lymphoblastic leukaemia and beta-thalassaemia major: potential cure of both marrow disordersP D Kottaridis, K Peggs, A Lawrence, et al.
The British Journal of Surgery|June 12, 2013
Raised haematocrit concentration and the risk of death and vascular complications after major surgeryK M Musallam, J B Porter, P M Sfeir, et al.
British Journal of Haematology|October 16, 1999
Role of FcgammaRI (CD64) in erythrocyte elimination and its up-regulation in thalassaemiaE Wiener, D Allen, R J Porter, et al.
Journal of Medicinal Chemistry|August 20, 1993
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potentialP S Dobbin, R C Hider, A D Hall, et al.
British Journal of Haematology|May 1, 1985
The kinetics of unmatched and HLA-matched 111in-labelled homologous platelets in recipients with chronic marrow hypoplasia and anti-platelet immunityA M Peters, J B Porter, S H Saverymuttu, et al.
British Journal of Haematology|September 1, 1993
Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyridin-4-one, CP94, relates to differing metabolism of the iron chelating siteJ B Porter, R D Abeysinghe, K P Hoyes, et al.
Annals of Hematology|October 23, 2012
Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudyJ B Porter, M S Elalfy, A T Taher, et al.
Circulation|October 6, 2009
Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia majorP Kirk, M Roughton, J B Porter, et al.
American Journal of Hematology|November 10, 2010
Quality of life in thalassemia: a comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US normsA Sobota, R Yamashita, Y Xu, et al.
Pageof 10